Related Experiment Video

Updated: Aug 28, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

MMP-2 inhibition prevents platelet activation in ischemia/reoxygenation conditions

Kornela Jagoda Hałucha1, Marta Banaszkiewicz1, Alina Rak-Pasikowska1

  • 1Division of Clinical Chemistry and Laboratory Hematology, Department of Medical Laboratory Diagnostics, Faculty of Pharmacy with Division of Medical Analytics, Wroclaw Medical University, Poland.

Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University
|September 22, 2022
PubMed
Abstract

Insights

Doxycycline preserves platelet aggregation and function during ischemia/reoxygenation (I/R) injury by inhibiting matrix metalloproteinase-2 (MMP-2). This study shows doxycycline protects platelets from I/R-induced damage.

Area of Science:

  • Cardiovascular Research
  • Hematology
  • Pharmacology

Background:

  • Platelets are crucial in myocardial infarction and ischemia/reoxygenation (I/R) injuries.
  • Platelets contain matrix metalloproteinases (MMPs) involved in arterial thrombosis.
  • Doxycycline, an MMP inhibitor, shows protective effects in I/R injuries.

Purpose of the Study:

  • To investigate doxycycline's impact on platelet activation and MMP-2 activity during I/R.
  • To evaluate doxycycline's protective mechanisms in platelet function under I/R conditions.

Main Methods:

  • Human platelets were subjected to chemical I/R with and without doxycycline (10 μM).
  • Flow cytometry assessed platelet activation markers and platelet microvesicles (PMVs).
  • Adenosine diphosphate (ADP)-induced aggregation and MMP-2 activity were measured.

Main Results:

  • Doxycycline reduced activated glycoprotein IIb/IIIa expression and increased CD63 expression on PMVs.
  • I/R significantly decreased ADP-dependent platelet aggregation compared to controls.
  • Doxycycline pretreatment tended to enhance ADP-dependent aggregation and increased MMP-2 activity in I/R platelets.

Conclusions:

  • Doxycycline attenuates platelet activation during I/R.
  • Inhibition of platelet MMP-2 by doxycycline preserves platelet aggregation ability, offering protection.
  • Doxycycline demonstrates potential therapeutic value in mitigating I/R-related platelet dysfunction.
Keywords:
doxycyclineischemiametalloproteinasesplateletsreperfusion

More Related Videos

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

782
Using Cell-substrate Impedance and Live Cell Imaging to Measure Real-time Changes in Cellular Adhesion and De-adhesion Induced by Matrix Modification09:11

Using Cell-substrate Impedance and Live Cell Imaging to Measure Real-time Changes in Cellular Adhesion and De-adhesion Induced by Matrix Modification

Published on: February 19, 2015

11.0K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
617
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K